News and Events

Hatchtech Mechanism of Action Data and Safety Study Published

28/11/2012 | Press Releases

Specialty pharmaceutical company Hatchtech Pty Ltd has published data describing the mechanism of action of the active ingredient (Ha44) in its lead product DeOvo™, a single application topical treatment for head lice. The company also announced that it had successfully completed a Thorough QT (TQT) study, a clinical safety assessment required by US and European regulators for nearly all new molecular entities.

Download PDF


Categories